<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Clin. Cancer Res.</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-0432</issn>
        <issn pub-type="epub">1557-3265</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC6642361</article-id>
        <article-id pub-id-type="pmcid-ver">PMC6642361.1</article-id>
        <article-id pub-id-type="pmcaid">6642361</article-id>
        <article-id pub-id-type="pmcaiid">6642361</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1533542</article-id>
        <article-id pub-id-type="pmid">29848569</article-id>
        <article-id pub-id-type="doi">10.1158/1078-0432.CCR-18-0078</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1533542</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1533542</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention.</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lowery</surname>
              <given-names initials="MA">Maeve A.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ptashkin</surname>
              <given-names initials="R">Ryan</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jordan</surname>
              <given-names initials="E">Emmet</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Berger</surname>
              <given-names initials="MF">Michael F.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zehir</surname>
              <given-names initials="A">Ahmet</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Capanu</surname>
              <given-names initials="M">Marinela</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kemeny</surname>
              <given-names initials="NE">Nancy E.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>O’Reilly</surname>
              <given-names initials="EM">Eileen M.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>El-Dika</surname>
              <given-names initials="I">Imane</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jarnagin</surname>
              <given-names initials="WR">William R.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Harding</surname>
              <given-names initials="JJ">James J.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>D’Angelica</surname>
              <given-names initials="MI">Michael I.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Cercek</surname>
              <given-names initials="A">Andrea</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hechtman</surname>
              <given-names initials="JF">Jaclyn F.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hyman</surname>
              <given-names initials="DM">David M.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Klimstra</surname>
              <given-names initials="DS">David S.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Saltz</surname>
              <given-names initials="LB">Leonard B.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Abou-Alfa</surname>
              <given-names initials="GK">Ghassan K.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Trinity College Dublin, Dublin, Ireland</aff>
        <aff id="A2"><label>2</label>Memorial Sloan Kettering Cancer Center, New York NY, USA</aff>
        <aff id="A3"><label>3</label>Weill Cornell Medical College, New York, NY, USA</aff>
        <author-notes>
          <corresp id="CR1"><underline>Corresponding author:</underline> Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, 300 East 66<sup>th</sup> st, New York, NY 10065, Telephone: 646 888 4543, Fax: 646 888 4542, <email>aboualg@mskcc.org</email></corresp>
          <fn fn-type="COI-statement" id="FN1">
            <p id="P27"><underline>Potential conflicts of interest:</underline> None for all authors</p>
          </fn>
        </author-notes>
        <pub-date pub-type="epub">
          <day>30</day>
          <month>5</month>
          <year>2018</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <day>01</day>
          <month>9</month>
          <year>2018</year>
        </pub-date>
        <volume>24</volume>
        <issue>17</issue>
        <issue-id pub-id-type="pmc-issue-id">338643</issue-id>
        <fpage>4154</fpage>
        <lpage>4161</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>16</day>
              <month>07</month>
              <year>2019</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>20</day>
              <month>07</month>
              <year>2019</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>20</day>
              <month>07</month>
              <year>2019</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-06-16 02:25:18.673">
              <day>16</day>
              <month>06</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1533542.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Purpose:</title>
            <p id="P1">Various genetic driver aberrations have been identified among distinct anatomic and clinical subtypes of intrahepatic and extrahepatic cholangiocarcinoma, and these molecular alterations may be prognostic biomarkers and/or predictive of drug response.</p>
          </sec>
          <sec id="S2">
            <title>Experimental Design:</title>
            <p id="P2">Tumor samples from patients with cholangiocarcinoma who consented prospectively were analyzed using the MSK-IMPACT platform, a targeted next generation sequencing assay that analyzes all exons and selected introns of 410 cancer-associated genes. Fisher’s exact tests were performed to identify associations between clinical characteristics and genetic alterations.</p>
          </sec>
          <sec id="S3">
            <title>Results:</title>
            <p id="P3">195 patients were studied: 78% intrahepatic and 22% extrahepatic cholangiocarcinoma. The most commonly altered genes in intrahepatic cholangiocarcinoma (IHC) were <italic toggle="yes">IDH1</italic> (30%), <italic toggle="yes">ARID1A</italic> (23%) <italic toggle="yes">BAP1</italic> (20%), <italic toggle="yes">TP53</italic> (20%) and <italic toggle="yes">FGFR2</italic> gene fusions (14%). A tendency towards mutual exclusivity was seen between multiple genes in IHC including <italic toggle="yes">TP53:IDH1</italic>, <italic toggle="yes">IDH1:KRAS</italic>, <italic toggle="yes">TP53:BAP1</italic>, <italic toggle="yes">IDH1:FGFR2</italic>. Alterations in CDKN2A/B and ERBB2 were associated with reduced survival and time to progression on chemotherapy in patients with locally advanced or metastatic disease. Genetic alterations with potential therapeutic implications were identified in 47% of patients, leading to biomarker directed therapy or clinical trial enrollment in 16% of patients.</p>
          </sec>
          <sec id="S4">
            <title>Conclusions:</title>
            <p id="P4">Cholangiocarcinoma is a genetically diverse cancer. Alterations in <italic toggle="yes">CDKN2A/B</italic> and <italic toggle="yes">ERBB2</italic> are associated with negative prognostic implications in patients with advanced disease. Somatic alterations with therapeutic implications were identified in almost half of patients. These prospective data provide a contemporary benchmark for guiding the development of targeted therapies in molecularly profiled cholangiocarcinoma, and support to the use of molecular profiling to guide therapy selection in patients with advanced biliary cancers.</p>
          </sec>
        </abstract>
        <abstract id="ABS2" abstract-type="summary">
          <title>Statement of translational relevance</title>
          <p id="P5">This report evaluates the prognostic and therapeutic implications of comprehensive genetic analysis of patients with advanced cholangiocarcinoma. Through targeted deep sequencing of all exons and selected introns of 410 key cancer-associated genes, we identified genetic alterations with potential therapeutic implications in 47% of patients, leading to biomarker directed therapy or clinical trial enrolment in 16% of patients. Correlation of genetic alterations with clinical outcomes demonstrated that alterations in CDKN2A/B and ERBB2 were associated with reduced overall survival and shorter time to progression on first line chemotherapy. These findings indicate that molecular profiling can facilitate enrollment of patients with cholangiocarcinoma to biomarker selected clinical trials, and that specific genotypes may have prognostic implications in terms of clinical outcomes.</p>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
